Zoledronic Acid in the treatment of bone metastases from the breast and prostate carcinoma.
Cancer patients, particulary those with bone metastatses, are at high risk of skeletal complications. Patients with advanced cancer and bone metastatses freguently experience debilitating skeletal complications that can substantially affect their quality of life.Many types of cancer metastasize to the bone, but breast and prostate cancer account for roughly 70-80% of bone metastatses. Bisphosphonates have emerged as a leading therapeutic intervention for the treatment and prevention of sceletal complications of malignancy. Bisphosphonates have a variety of activities in bone and can effectively normalize serum calcium, delay the onset and reduce the incidence of sceletal complications, and may reduce bone pain. Zoledronic Acid is highly potent, new-generation, nitrogen-containing bisphosphonate that has superior potency and pharmacologic properties compared with other bisphosphonates. It has been shown to be highly effective in the treatment of osteolitic, mixed and osteoblastic bone metastatses in patients with breast cancer and prostate cancer.